Protein Kinase Inhibitors: all 15,038 studies that test it

Page 80 of 151. Open to participants first (2,480), then studies with results posted, then the rest; newest registration first within each.

• A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung CancerStatus unknownNCT05380024Phase 2
• Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid TumorsActive, not recruitingNCT05379946Phase 1/2
• A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 MutationsSuspendedNCT05378763Phase 3
• Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsCompletedNCT05375994Phase 1/2
• TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical TrailCompletedNCT05375461Phase 3
• Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05374603Phase 2
• Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later LineStatus unknownNCT05372198Phase 2
• A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene AlterationsStatus unknownNCT05372120Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisActive, not recruitingNCT05371964Phase 1
• Mass Balance Study of [14C]ChiauranibCompletedNCT05371899Not applicable
• Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent ThromboinflammationWithdrawnNCT05371275Phase 2
• A Clinical Trial of Regorafenib in Patients With Pretreated Advanced MelanomaActive, not recruitingNCT05370807Phase 2
• A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male SubjectsCompletedNCT05369858Phase 1
• Fruquintinib DDI Study With P-gp and BCRP SubstratesCompletedNCT05368805Phase 1
• ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian CancerWithdrawnNCT05368506Early Phase 1
• A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian ParticipantsStatus unknownNCT05367388Phase 1
• To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerActive, not recruitingNCT05365178Phase 3
• A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHLWithdrawnNCT05365100Phase 1/2
• Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
• Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung CancerWithdrawnNCT05364645Phase 2
• Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsActive, not recruitingNCT05364073Phase 1
• Seleno-L Methionine (SLM)-Axitinib-PembrolizumabActive, not recruitingNCT05363631Phase 1/2
• Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate CancerSuspendedNCT05361915Phase 2
• A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.Status unknownNCT05361564Phase 2
• Baricitinib for Cutaneous DermatomyositisWithdrawnNCT05361109Phase 2
• A Study on the Effect of AB-106 on the Pharmacokinetics of DigoxinCompletedNCT05357911Phase 1
• A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PKCompletedNCT05357820Phase 1
• Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyWithdrawnNCT05356897Phase 2
• An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult PatientsTerminatedNCT05356858Phase 2
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.Active, not recruitingNCT05355701Phase 1
• ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic CancerActive, not recruitingNCT05355298Phase 1/2
• A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedNCT05354362Phase 1
• A Phase I Clinical Study on SHR6390 in Healthy Chinese VolunteersCompletedNCT05354336Phase 1
• HAIC Combined With Toripalimab and Donafenib for Advanced BTCStatus unknownNCT05350943Phase 2
• Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT05348577Phase 3
• Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host DiseaseStatus unknownNCT05348096Phase 2
• Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05347628Phase 1
• A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)Active, not recruitingNCT05347225Phase 1
• Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy VolunteersCompletedNCT05346601Phase 1
• Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult SubjectsCompletedNCT05344729Phase 1
• Daily Topical Rapamycin for VitiligoActive, not recruitingNCT05342519Phase 2
• A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668Status unknownNCT05341570Phase 1
• NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)CompletedNCT05340621Phase 1/2
• A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological MalignanciesTerminatedNCT05338346Phase 1
• A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast CancerStatus unknownNCT05337657Phase 1
• A Phase II Study of Chiauranib in Combine With Capecitabine in TNBCTerminatedNCT05336721Phase 2
• Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667CompletedNCT05335447Phase 1
• Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung DiseaseTerminatedNCT05335278Not applicable
• GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingNCT05335018Phase 2
• Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy ParticipantsCompletedNCT05330858Phase 1
• GM-CLAG in Relapsed/Refractory FLT3-mutated AMLWithdrawnNCT05330377Phase 1
• A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid TumorsStatus unknownNCT05329298Phase 1/2
• An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTCStatus unknownNCT05327582Phase 1/2
• IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Phase 1
• Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.Status unknownNCT05326425Phase 2
• A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial SpondyloarthritisStatus unknownNCT05324631Phase 3
• Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibActive, not recruitingNCT05323955Phase 2
• Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLLStatus unknownNCT05322733Phase 2
• Zanubrutinib for HLHCompletedNCT05320575Phase 3
• Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2
• Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT05319028Phase 2
• A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different ManufacturersCompletedNCT05318820Early Phase 1
• Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With VenetoclaxTerminatedNCT05317936Phase 1/2
• DDI Study of OrelabrutinibCompletedNCT05316857Phase 1
• A Food-Effect Study of BPI-16350 in Healthy SubjectsCompletedNCT05316259Phase 1
• Study of Erdafitinib Intravesical Delivery System for Localized Bladder CancerActive, not recruitingNCT05316155Phase 1/2
• Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic EventsCompletedNCT05313620Phase 4
• Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05312216Phase 2
• Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.Status unknownNCT05311943Phase 3
• Niraparib Plus Anlotinib for Recurrent Ovarian CancerStatus unknownNCT05311579Phase 2
• A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingNCT05307705Phase 1
• Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia PatientsActive, not recruitingNCT05306301Phase 2
• A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy ParticipantsCompletedNCT05303220Phase 1
• Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3
• A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue SarcomaCompletedNCT05301764Phase 1/2
• A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic SclerosisActive, not recruitingNCT05300932Phase 4
• Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.Active, not recruitingNCT05300438Phase 1
• Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA MutationsTerminatedNCT05300048Phase 1
• "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"WithdrawnNCT05299580Phase 2
• Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsCompletedNCT05299125Phase 2
• Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC TumorsCompletedNCT05298176Phase 2
• A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerActive, not recruitingNCT05297890Phase 2
• Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast CancerActive, not recruitingNCT05296746Phase 2
• Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerActive, not recruitingNCT05296512Phase 2
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• Role of Tofacitinib in Vitiligo PatientsStatus unknownNCT05293119Early Phase 1
• Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRCStatus unknownNCT05292417Phase 2
• Descemet Endothelial Thickness Comparison Trial IActive, not recruitingNCT05289661Phase 3
• Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
• A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard TherapyStatus unknownNCT05287386Phase 2
• A Study Comparing Four Different Rivoceranib Tablets in Healthy ParticipantsCompletedNCT05287360Phase 1
• Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With LetrozoleActive, not recruitingNCT05286437Phase 2
• TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerStatus unknownNCT05284994Phase 1/2
• A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male ParticipantsCompletedNCT05284890Phase 1
• A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderStatus unknownNCT05284175Not applicable
• Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic FunctionCompletedNCT05283915Phase 1
• Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT05282433Phase 2
• Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.CompletedNCT05282030Phase 1
• A Study of Zanubrutinib in Patients With ITPCompletedNCT05279872Phase 2
• A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic MalignanciesWithdrawnNCT05279859Phase 1/2

← Protein Kinase Inhibitors overview